 <h1>Telzir Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>fosamprenavir</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about fosamprenavir. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Telzir.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to fosamprenavir: oral suspension, oral tablet</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, fosamprenavir (the active ingredient contained in Telzir) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking fosamprenavir:</p><p>
<i>More common</i>
</p><ul>
<li>Black, tarry stools</li>
<li>chills</li>
<li>cough</li>
<li>fever</li>
<li>lower back or side pain</li>
<li>painful or difficult urination</li>
<li>pale skin</li>
<li>skin rash</li>
<li>sore throat</li>
<li>ulcers, sores, or white spots in the mouth</li>
<li>unusual bleeding or bruising</li>
<li>unusual tiredness or weakness</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Blistering, peeling, loosening of the skin</li>
<li>blood in the urine</li>
<li>chest pain or discomfort</li>
<li>diarrhea</li>
<li>itching</li>
<li>joint or muscle pain</li>
<li>large amount of cholesterol in the blood</li>
<li>large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or genitals</li>
<li>nausea</li>
<li>pain in the groin or genitals</li>
<li>pain or discomfort in the arms, jaw, back, or neck</li>
<li>red skin lesions, often with a purple center</li>
<li>red, irritated eyes</li>
<li>sharp back pain just below the ribs</li>
<li>sweating</li>
<li>vomiting</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of fosamprenavir may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>Less common</i>
</p><ul>
<li>Headache</li>
<li>stomach pain</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings in the mouth</li>
</ul><p>
<!-- end oral suspension, oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to fosamprenavir: oral suspension, oral tablet</i></p><h3>General</h3><p>Diarrhea, rash, nausea, vomiting, and headache were the most frequent moderate to severe side effects in clinical trials.  Discontinuations due to side effects were 6.4% in patients using this drug compared to 5.9% in those using comparator therapies; the most common side effects leading to discontinuation of this drug (incidence up to 1%) included diarrhea, nausea, vomiting, increased AST, increased ALT, and rash.<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>Skin rash (regardless of causality) was reported in about 19% of patients.  Rashes were generally maculopapular and of mild or moderate intensity, some with pruritus.  Rash had a median onset and duration of 11 and 13 days, respectively, and led to discontinuation of this drug in less than 1% of patients.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Skin rash (up to 19%)</p>
<p><b>Common</b> (1% to 10%): Rash/cutaneous reactions (including erythematous or maculopapular cutaneous eruptions [with or without pruritus])</p>
<p><b>Rare</b> (0.01% to 0.1%): Severe and/or life-threatening skin reactions (including Stevens-Johnson syndrome)</p>
<p><b>Frequency not reported</b>: Erythema multiforme, pruritus</p>
<p><b>Postmarketing reports</b>: Angioedema</p>
<p></p>
<p>Protease inhibitors:</p>
<p>-Frequency not reported: Lipohypertrophy<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (up to 13%)</p>
<p><b>Common</b> (1% to 10%): Nausea, vomiting, abdominal pain, increased serum lipase, loose stools, gastritis, abdominal distension, upper abdominal pain, flatulence</p>
<p><b>Uncommon</b> (0.1% to 1%): Gastroesophageal reflux disease</p>
<p><b>Frequency not reported</b>: Increased amylase</p>
<p><b>Postmarketing reports</b>: Oral paresthesia<sup>[Ref]</sup></p><p>Increased serum lipase (greater than 2 times the upper limit of normal [2 x ULN]) has been reported in up to 8% of patients.</p>
<p></p>
<p>Vomiting was reported more often in pediatric patients than adult patients.<sup>[Ref]</sup></p><h3>Other</h3><p>Increased fasting triglycerides (greater than 750 mg/dL) have been reported in up to 11% of patients.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Increased fasting triglycerides (up to 11%)</p>
<p><b>Common</b> (1% to 10%): Fatigue</p>
<p><b>Uncommon</b> (0.1% to 1%): Pyrexia, increased cholesterol</p>
<p></p>
<p>Antiretroviral therapy:</p>
<p>-Frequency not reported: Increased weight, increased blood lipids<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Elevated ALT, elevated AST</p>
<p><b>Frequency not reported</b>: Liver toxicity<sup>[Ref]</sup></p><p>Elevated ALT (greater than 5 x ULN) and AST (greater than 5 x ULN) have been reported in up to 8% and up to 6% of patients, respectively.<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Decreased absolute neutrophil count (less than 750 cells/mm3) has been reported in 3% of patients.</p>
<p></p>
<p>Neutropenia was reported more often in pediatric patients than adult patients.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Decreased absolute neutrophil count, neutropenia</p>
<p></p>
<p>Amprenavir:</p>
<p>-Frequency not reported: Acute hemolytic anemia</p>
<p></p>
<p>Protease inhibitors:</p>
<p>-Frequency not reported: Spontaneous bleeding in patients with hemophilia A and B<sup>[Ref]</sup></p><h3>Metabolic</h3><p>Increased glucose (greater than 251 mg/dL) has been reported in 2% of patients.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Increased glucose, hyperlipidemia, hypertriglyceridemia</p>
<p><b>Uncommon</b> (0.1% to 1%): Anorexia</p>
<p><b>Frequency not reported</b>: Hyperglycemia, increased body fat</p>
<p><b>Postmarketing reports</b>: Hypercholesterolemia</p>
<p></p>
<p>Protease inhibitors:</p>
<p>-Frequency not reported: Hypertriglyceridemia, hypercholesterolemia, resistance to insulin</p>
<p>-Postmarketing reports: New onset diabetes mellitus, exacerbation of preexisting diabetes mellitus, hyperglycemia, diabetic ketoacidosis</p>
<p></p>
<p>Antiretroviral therapy:</p>
<p>-Frequency not reported: Increased glucose<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Headache, dizziness<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Drug hypersensitivity<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Postmarketing reports</b>: Myocardial infarction<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Postmarketing reports</b>: Nephrolithiasis<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Frequency not reported</b>: Elevated creatine kinase, osteonecrosis</p>
<p></p>
<p>Protease inhibitors:</p>
<p>-Rare (0.01% to 0.1%): Rhabdomyolysis</p>
<p>-Frequency not reported: Increased creatine phosphokinase, myalgia, myositis<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Frequency not reported</b>: Depressive/mood disorders<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Frequency not reported</b>: Immune reconstitution/reactivation syndrome, autoimmune disorders in the setting of immune reconstitution (e.g., Graves' disease, polymyositis, Guillain-Barre syndrome)<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV "Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Available from: URL: https://aidsinfo.nih.gov/contentfiles/lvguidelines/pediatricguidelines.pdf."   ([2018, May 22):</p><p id="ref_2">2. "Drugs for HIV infection." Treat Guidel Med Lett 7 (2009): 11-22</p><p id="ref_3">3. Panel on Antiretroviral Guidelines for Adults and Adolescents "Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. Available from: URL: https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf."   ([2018, May 30]):</p><p id="ref_4">4. Warnke D,  Barreto J,  Temesgen Z "Antiretroviral drugs." J Clin Pharmacol 47 (2007): 1570-9</p><p id="ref_5">5. Hester EK,  Chandler HV,  Sims KM "Fosamprenavir: drug development for adherence." Ann Pharmacother 40 (2006): 1301-10</p><p id="ref_6">6. Borras-Blasco J,  Navarro-Ruiz A,  Borras C,  Castera E "Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection." J Antimicrob Chemother 62 (2008): 879-88</p><p id="ref_7">7. Eron J Jr,  Yeni P,  Gathe J Jr, et al. "The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial." Lancet 368 (2006): 476-82</p><p id="ref_8">8. Ruane PJ,  Luber AD,  Wire MB, et al. "Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams fosamprenavir once daily in combination with either 100 OR 200 milligrams of ritonavir in healthy volunteers." Antimicrob Agents Chemother 51 (2006): 560-5</p><p id="ref_9">9. Wire MB,  Baker KL,  Jones LS, et al. "Ritonavir Increases Plasma Amprenavir (APV) Exposure to a Similar Extent when Coadministered with either Fosamprenavir or APV." Antimicrob Agents Chemother 50 (2006): 1578-80</p><p id="ref_10">10. Shelton MJ,  Wire MB,  Lou Y,  Adamkiewicz B,  Min SS "Pharmacokinetic and safety evaluation of high-dose combinations of fosamprenavir and ritonavir." Antimicrob Agents Chemother 50 (2006): 928-34</p><p id="ref_11">11. Pavel S,  Burty C,  Alcaraz I, et al. "Severe liver toxicity in postexposure prophylaxis for HIV infection with a zidovudine, lamivudine and fosamprenavir/ritonavir regimen." AIDS 21 (2007): 268-269</p><p id="ref_12">12. "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC. </p><p id="ref_13">13. Piacenti FJ "An update and review of antiretroviral therapy." Pharmacotherapy 26 (2006): 1111-33</p><p id="ref_14">14. Gathe JC Jr,  Ive P,  Wood R, et al. "SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients." AIDS 18 (2004): 1529-1537</p><p id="ref_15">15. Arvieux C,  Tribut O "Amprenavir or Fosamprenavir plus Ritonavir in HIV Infection: Pharmacology, Efficacy and Tolerability Profile." Drugs 65 (2005): 633-59</p><p id="ref_16">16. Gathe JC Jr,  Wood R,  Sanne I, et al. "Long-Term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: An uncontrolled, open-label, single-arm follow-on study." Clin Ther 28 (2006): 745-54</p><p id="ref_17">17. Soriano V,  Puoti M,  Sulkowski M, et al. "Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel." AIDS 21 (2007): 1073-89</p><p id="ref_18">18. Bergersen BM "Cardiovascular Risk in Patients with HIV Infection : Impact of Antiretroviral Therapy." Drugs 66 (2006): 1971-87</p><p id="ref_19">19. Calza L,  Manfredi R,  Verucchi G "Myocardial infarction risk in HIV-infected patients: epidemiology, pathogenesis,  and clinical management." AIDS 24 (2010): 789-802</p></div>
<div class="more-resources" id="moreResources">
<h2>More about Telzir (fosamprenavir)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Drug class: protease inhibitors</li>
</ul>
<h3>Consumer resources</h3>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Lexiva</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>HIV Infection</li>
<li>Nonoccupational Exposure</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to fosamprenavir: oral suspension, oral tablet</i></p><h3>General</h3><p>Diarrhea, rash, nausea, vomiting, and headache were the most frequent moderate to severe side effects in clinical trials.  Discontinuations due to side effects were 6.4% in patients using this drug compared to 5.9% in those using comparator therapies; the most common side effects leading to discontinuation of this drug (incidence up to 1%) included diarrhea, nausea, vomiting, increased AST, increased ALT, and rash.<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>Skin rash (regardless of causality) was reported in about 19% of patients.  Rashes were generally maculopapular and of mild or moderate intensity, some with pruritus.  Rash had a median onset and duration of 11 and 13 days, respectively, and led to discontinuation of this drug in less than 1% of patients.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Skin rash (up to 19%)</p><p><b>Common</b> (1% to 10%): Rash/cutaneous reactions (including erythematous or maculopapular cutaneous eruptions [with or without pruritus])</p><p><b>Rare</b> (0.01% to 0.1%): Severe and/or life-threatening skin reactions (including Stevens-Johnson syndrome)</p><p><b>Frequency not reported</b>: Erythema multiforme, pruritus</p><p><b>Postmarketing reports</b>: Angioedema</p><p></p><p>Protease inhibitors:</p><p>-Frequency not reported: Lipohypertrophy<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (up to 13%)</p><p><b>Common</b> (1% to 10%): Nausea, vomiting, abdominal pain, increased serum lipase, loose stools, gastritis, abdominal distension, upper abdominal pain, flatulence</p><p><b>Uncommon</b> (0.1% to 1%): Gastroesophageal reflux disease</p><p><b>Frequency not reported</b>: Increased amylase</p><p><b>Postmarketing reports</b>: Oral paresthesia<sup>[Ref]</sup></p><p>Increased serum lipase (greater than 2 times the upper limit of normal [2 x ULN]) has been reported in up to 8% of patients.</p><p></p><p>Vomiting was reported more often in pediatric patients than adult patients.<sup>[Ref]</sup></p><h3>Other</h3><p>Increased fasting triglycerides (greater than 750 mg/dL) have been reported in up to 11% of patients.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Increased fasting triglycerides (up to 11%)</p><p><b>Common</b> (1% to 10%): Fatigue</p><p><b>Uncommon</b> (0.1% to 1%): Pyrexia, increased cholesterol</p><p></p><p>Antiretroviral therapy:</p><p>-Frequency not reported: Increased weight, increased blood lipids<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Elevated ALT, elevated AST</p><p><b>Frequency not reported</b>: Liver toxicity<sup>[Ref]</sup></p><p>Elevated ALT (greater than 5 x ULN) and AST (greater than 5 x ULN) have been reported in up to 8% and up to 6% of patients, respectively.<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Decreased absolute neutrophil count (less than 750 cells/mm3) has been reported in 3% of patients.</p><p></p><p>Neutropenia was reported more often in pediatric patients than adult patients.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Decreased absolute neutrophil count, neutropenia</p><p></p><p>Amprenavir:</p><p>-Frequency not reported: Acute hemolytic anemia</p><p></p><p>Protease inhibitors:</p><p>-Frequency not reported: Spontaneous bleeding in patients with hemophilia A and B<sup>[Ref]</sup></p><h3>Metabolic</h3><p>Increased glucose (greater than 251 mg/dL) has been reported in 2% of patients.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Increased glucose, hyperlipidemia, hypertriglyceridemia</p><p><b>Uncommon</b> (0.1% to 1%): Anorexia</p><p><b>Frequency not reported</b>: Hyperglycemia, increased body fat</p><p><b>Postmarketing reports</b>: Hypercholesterolemia</p><p></p><p>Protease inhibitors:</p><p>-Frequency not reported: Hypertriglyceridemia, hypercholesterolemia, resistance to insulin</p><p>-Postmarketing reports: New onset diabetes mellitus, exacerbation of preexisting diabetes mellitus, hyperglycemia, diabetic ketoacidosis</p><p></p><p>Antiretroviral therapy:</p><p>-Frequency not reported: Increased glucose<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Headache, dizziness<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Drug hypersensitivity<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Postmarketing reports</b>: Myocardial infarction<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Postmarketing reports</b>: Nephrolithiasis<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Frequency not reported</b>: Elevated creatine kinase, osteonecrosis</p><p></p><p>Protease inhibitors:</p><p>-Rare (0.01% to 0.1%): Rhabdomyolysis</p><p>-Frequency not reported: Increased creatine phosphokinase, myalgia, myositis<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Frequency not reported</b>: Depressive/mood disorders<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Frequency not reported</b>: Immune reconstitution/reactivation syndrome, autoimmune disorders in the setting of immune reconstitution (e.g., Graves' disease, polymyositis, Guillain-Barre syndrome)<sup>[Ref]</sup></p><p id="ref_1">1. Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV "Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Available from: URL: https://aidsinfo.nih.gov/contentfiles/lvguidelines/pediatricguidelines.pdf."   ([2018, May 22):</p><p id="ref_2">2. "Drugs for HIV infection." Treat Guidel Med Lett 7 (2009): 11-22</p><p id="ref_3">3. Panel on Antiretroviral Guidelines for Adults and Adolescents "Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. Available from: URL: https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf."   ([2018, May 30]):</p><p id="ref_4">4. Warnke D,  Barreto J,  Temesgen Z "Antiretroviral drugs." J Clin Pharmacol 47 (2007): 1570-9</p><p id="ref_5">5. Hester EK,  Chandler HV,  Sims KM "Fosamprenavir: drug development for adherence." Ann Pharmacother 40 (2006): 1301-10</p><p id="ref_6">6. Borras-Blasco J,  Navarro-Ruiz A,  Borras C,  Castera E "Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection." J Antimicrob Chemother 62 (2008): 879-88</p><p id="ref_7">7. Eron J Jr,  Yeni P,  Gathe J Jr, et al. "The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial." Lancet 368 (2006): 476-82</p><p id="ref_8">8. Ruane PJ,  Luber AD,  Wire MB, et al. "Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams fosamprenavir once daily in combination with either 100 OR 200 milligrams of ritonavir in healthy volunteers." Antimicrob Agents Chemother 51 (2006): 560-5</p><p id="ref_9">9. Wire MB,  Baker KL,  Jones LS, et al. "Ritonavir Increases Plasma Amprenavir (APV) Exposure to a Similar Extent when Coadministered with either Fosamprenavir or APV." Antimicrob Agents Chemother 50 (2006): 1578-80</p><p id="ref_10">10. Shelton MJ,  Wire MB,  Lou Y,  Adamkiewicz B,  Min SS "Pharmacokinetic and safety evaluation of high-dose combinations of fosamprenavir and ritonavir." Antimicrob Agents Chemother 50 (2006): 928-34</p><p id="ref_11">11. Pavel S,  Burty C,  Alcaraz I, et al. "Severe liver toxicity in postexposure prophylaxis for HIV infection with a zidovudine, lamivudine and fosamprenavir/ritonavir regimen." AIDS 21 (2007): 268-269</p><p id="ref_12">12. "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC. </p><p id="ref_13">13. Piacenti FJ "An update and review of antiretroviral therapy." Pharmacotherapy 26 (2006): 1111-33</p><p id="ref_14">14. Gathe JC Jr,  Ive P,  Wood R, et al. "SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients." AIDS 18 (2004): 1529-1537</p><p id="ref_15">15. Arvieux C,  Tribut O "Amprenavir or Fosamprenavir plus Ritonavir in HIV Infection: Pharmacology, Efficacy and Tolerability Profile." Drugs 65 (2005): 633-59</p><p id="ref_16">16. Gathe JC Jr,  Wood R,  Sanne I, et al. "Long-Term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: An uncontrolled, open-label, single-arm follow-on study." Clin Ther 28 (2006): 745-54</p><p id="ref_17">17. Soriano V,  Puoti M,  Sulkowski M, et al. "Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel." AIDS 21 (2007): 1073-89</p><p id="ref_18">18. Bergersen BM "Cardiovascular Risk in Patients with HIV Infection : Impact of Antiretroviral Therapy." Drugs 66 (2006): 1971-87</p><p id="ref_19">19. Calza L,  Manfredi R,  Verucchi G "Myocardial infarction risk in HIV-infected patients: epidemiology, pathogenesis,  and clinical management." AIDS 24 (2010): 789-802</p><h2>More about Telzir (fosamprenavir)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Drug class: protease inhibitors</li>
</ul><h3>Consumer resources</h3><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>HIV Infection</li>
<li>Nonoccupational Exposure</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>